Loading...
The GLP-1 Advanced Panel expands on the GLP-1 Essentials Panel by evaluating additional organ systems and hormonal pathways that influence both the benefits and risks of GLP-1 medications. It is especially useful for patients pursuing aggressive metabolic improvement, longevity goals, or long-term therapy.
Pancreatic enzymes amylase and lipase are included to monitor for pancreatic stress, which is uncommon but clinically important to detect early. ApoB provides a more accurate measure of atherogenic lipoprotein burden than LDL alone, helping assess true cardiovascular risk reduction during treatment. Uric acid is tracked because rapid weight loss and changes in insulin levels can transiently raise levels and trigger gout in susceptible individuals.
Thyroid markers TSH, free T4, and free T3 help identify thyroid dysfunction that can blunt fat loss, mimic GLP-1 side effects like fatigue, or complicate dose adjustments. Ferritin, albumin, total protein, and globulin provide insight into nutritional status, inflammation, and protein intake during appetite suppression. Testosterone adds important context for body composition, energy, and metabolic health, particularly in men.
Kidney markers BUN and creatinine assess renal safety during weight loss and changes in blood pressure or hydration. A full blood count including red cells, white cells, and platelets helps detect anemia, nutrient deficiencies, inflammation, or immune changes that may not be clinically obvious early on. Additional liver markers including ALP and bilirubin give a more complete picture of bile flow and liver adaptation as fat mass and insulin resistance improve.
Repeated over time, the GLP-1 Advanced Panel allows you to distinguish expected physiologic changes from true adverse effects, personalize dosing, and ensure that metabolic gains are not coming at the expense of long-term health.